Compare
Revium Rx. vs Xenetic Biosciences, Inc. vs GT Biopharma, Inc. vs Palatin Technologies Inc
| Latest fiscal year | Revium Rx. RVRC | Xenetic Biosciences, Inc. XBIO | GT Biopharma, Inc. GTBP | Palatin Technologies Inc PTN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | n/a | $2.98M | n/a | $13.19M |
| Revenue growth (YoY) | n/a | +19.0% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -95.2% | n/a | -65.7% |
| Net margin | n/a | -90.1% | n/a | -63.5% |
| Net income | -$13.45M | -$2.68M | -$28.35M | -$8.38M |
| EPS (Diluted) | -$0.22 | -$1.58 | -$6.68 | -$2.96 |
| Operating cash flow | n/a | -$2.29M | -$12.91M | -$13.53M |
| Free cash flow | n/a | n/a | n/a | -$13.58M |
| Cash & equivalents | $1.68M | n/a | $6.81M | $7.49M |
| Total assets | $8.30M | $8.36M | $8.11M | $8.52M |
| Total liabilities | $1.42M | $968.0K | n/a | $1.84M |
| Shareholders' equity | $6.88M | $7.40M | $5.79M | $6.69M |
| Return on year-end equity | -195.5% | -36.2% | -490.0% | -125.3% |
| Shares outstanding | 60.73M | 2.29M | 25.53M | 1.78M |
Revenue, most recent five fiscal years
| Fiscal year | Revium Rx. | Xenetic Biosciences, Inc. | GT Biopharma, Inc. | Palatin Technologies Inc |
|---|---|---|---|---|
| Latest | n/a | $2.98M Ended 2025-12-31 | $0 Ended 2020-12-31 | $13.19M Ended 2026-06-30 |
| 1 year earlier | n/a | $2.50M Ended 2024-12-31 | $0 Ended 2019-12-31 | n/a |
| 2 years earlier | n/a | $2.54M Ended 2023-12-31 | n/a | n/a |
| 3 years earlier | n/a | $1.71M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $1.16M Ended 2021-12-31 | n/a | n/a |